Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

FSD Pharma Inc. (C:HUGE)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: First Canadian Place
100 King Street West, Suite 4000
Tel: N/A
IR: See website
Key People
Zeeshan Saeed
Executive Co-Chairman, President
Anthony Durkacz
Co-Chairman of the Board, Interim Chief Executive Officer, Executive Director
Nathan Coyle
Interim Chief Financial Officer
Sara May
President of FV Pharma Inc
Huma Qamar
Senior Vice President, Head of R&D Program
Sandra Lottes
Vice President, Head of Clinical Research of FSD Pharma's BioSciences Division
Edward Brennan
Chief Medical Officer
Shahzad Shah
Chief Operating Officer of FV Pharma
Business Overview
Financial Overview
For the fiscal year ended 31 December 2021, FSD Pharma Inc revenues was not reported. Net loss before extraordinary items increased 19% to $33.9M. Higher net loss reflects General and administrative increase of 58% to $15.9M (expense), Effective G/L on Derivatives - Hedging decrease of 73% to $683K (income), Loss (gain) on settlement of financial l decrease of 93% to $50K (income).
Employees: 10 as of Dec 31, 2021
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $0.00M as of Mar 31, 2022
EBITDA (TTM): -$38.27M as of Mar 31, 2022
Net annual income (TTM): -$43.74M as of Mar 31, 2022
Free cash flow (TTM): -$27.38M as of Mar 31, 2022
Net Debt Last Fiscal Year: N/A
Shares outstanding: 38,504,810 as of May 2, 2022
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization